per-chart, page-830

things are not looking good for Sarepta..
Sp keeps falling
Tells me
investors are selling in the belief that the FDA will not approve SRP901 for the whole DMD population..
due on the 21st of June or before..

What does it mean for Sarepta

Srp901 a gene therapy drug will not be financial without a larger population
so
all 4 of Sareptas drugs don’t show efficacy .. FDA could put pressure on Sarepta to correct that

Per with proven ( combination therapy) could help keep Sareptas drugs on the ma
rket.
Per as spoken by Management could treat 100% of the DMD market…